What Is ACP-105?
ACP-105 is a nonsteroidal selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals, one of the lesser-studied compounds in the SARM class with a comparatively small published research footprint.
Mechanism of Action
Like other SARMs, ACP-105 is studied for selective androgen receptor activation intended to produce anabolic effects in muscle and bone tissue with reduced activity in other androgen-sensitive tissue, though the specific preclinical dataset supporting this for ACP-105 is considerably smaller than for better-studied SARMs.
Studied Benefits
These are effects ACP-105 has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
🧬
Early-Stage SARM Research
ACP-105 originates from the same Ligand Pharmaceuticals SARM discovery program associated with LGD-4033, but has a much more limited independently published research record, with most available information sourced from patent filings rather than peer-reviewed trial data.
⚡
Comparative SARM-Class Research
Researchers examining ACP-105 typically do so in the context of comparing structure-activity relationships across the broader SARM class rather than as a standalone, independently well-characterized compound.
Dosing Guide
What the research shows
No dosage of any kind has been clinically validated for ACP-105 in humans. Any figures found outside patent-level preclinical data should be treated as unverified.
Compound X does not provide dosing recommendations. ACP-105 is sold for laboratory research use only and is not intended for human consumption.
Reported Side Effects
Because independently published research on ACP-105 is limited primarily to patent-level data, its human safety profile is essentially uncharacterized. It has never been evaluated in human clinical trials, is not FDA-approved, and no meaningful human safety data exists.
FAQ
Is ACP-105 FDA-approved?
No. ACP-105 is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
What is ACP-105 commonly studied for?
Early-Stage SARM Research — ACP-105 originates from the same Ligand Pharmaceuticals SARM discovery program associated with LGD-4033, but has a much more limited independently published research record, with most available information sourced from patent filings rather than peer-reviewed trial data.
Is ACP-105 legal to buy in the US?
In the US, UK, Canada and Australia, ACP-105 is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
References
Limited available ACP-105 information is found in Ligand Pharmaceuticals patent filings and general SARM-class review literature indexed on PubMed under "selective androgen receptor modulator ACP-105."
